Keros Therapeutics, Inc.

NASDAQ (USD): Keros Therapeutics, Inc. (KROS)

Last Price

10.86

Today's Change

+0.34 (3.23%)

Day's Change

10.74 - 11.63

Trading Volume

2,961,551

Overview

Market Cap

439 Million

Shares Outstanding

40 Million

Avg Volume

1,247,554

Avg Price (50 Days)

40.52

Avg Price (200 Days)

49.72

PE Ratio

-2.08

EPS

-5.22

Earnings Announcement

26-Feb-2025

Previous Close

10.52

Open

11.00

Day's Range

10.74 - 11.63

Year Range

9.775 - 73.0

Trading Volume

2,961,551

Price Change Highlight

1 Day Change

3.23%

5 Day Change

-22.43%

1 Month Change

-36.60%

3 Month Change

-82.27%

6 Month Change

-77.38%

Ytd Change

-31.78%

1 Year Change

-79.06%

3 Year Change

-77.52%

5 Year Change

-45.92%

10 Year Change

-45.92%

Max Change

-45.92%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment